| Market Capitalization (Millions $) |
1,329 |
| Shares
Outstanding (Millions) |
53 |
| Employees |
643 |
| Revenues (TTM) (Millions $) |
313 |
| Net Income (TTM) (Millions $) |
-144 |
| Cash Flow (TTM) (Millions $) |
19 |
| Capital Exp. (TTM) (Millions $) |
0 |
Caredx Inc
CardeDX Inc. is a commercial-stage precision medicine company that specializes in developing clinically actionable diagnostics to advance the field of transplant medicine. The company is based in Brisbane, California, and was founded in 2011. Its products and services are aimed at improving patient outcomes by providing accurate and reliable information about their transplant status.
Caredx's primary focus is on providing organ transplant patients with the latest diagnostic tools to ensure the best possible patient outcomes. The company's products and services are designed to help clinicians predict the likelihood of transplant rejection, monitor transplant patients for potential complications, and provide personalized treatment plans to prevent organ rejection.
Caredx's flagship product, the AlloSuree test, is a blood test that measures the fraction of donor-derived cell-free DNA circulating in a transplant recipient's bloodstream. The test provides clinicians with valuable information about the health of transplanted organs and helps to identify whether a patient is rejecting the transplant. The AlloSure test is the first and only commercially available test of its kind, and it is currently available in the United States and select international markets.
In addition to the AlloSure test, Caredx also offers a range of other diagnostic solutions for transplant patients, including the AlloMape test, which measures the expression of genes associated with organ rejection, and the AlloSeqe HLA genotyping test, which helps to identify the compatibility between a donor and recipient.
Caredx's services are primarily used by transplant centers, hospitals, and transplant specialists. The company has established partnerships with many leading academic medical centers and transplant organizations in the United States and internationally.
The company has a strong focus on research and development and has invested heavily in building a cutting-edge laboratory facility that allows for the development and testing of novel transplant diagnostics. In addition to developing new products and services, Caredx also works closely with transplant centers and transplant professionals to educate them about the latest advances in transplant diagnostic technology.
Caredx has received numerous awards and recognitions for its innovative products and services, including the 2016 Frost & Sullivan Technology Innovation Award and the 2018 Red Herring Top 100 North America Award.
Overall, Caredx is a leading player in the fast-growing field of precision medicine and is at the forefront of driving innovation and advancement in transplant diagnostics. With a strong commitment to research and development, the company is well-positioned to continue to grow and expand its product offerings and contribute to improving patient outcomes in the field of transplant medicine.
Company Address: 8000 Marina Boulevard, 4th Floor Brisbane 94005 CA
Company Phone Number: 287-2300 Stock Exchange / Ticker: NASDAQ CDNA
|
14.04% 
95.41 %